Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 83 points (-0.5%) at 16,448 as of Tuesday, May 6, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,223 issues advancing vs. 1,760 declining with 164 unchanged. The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.4%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 2.8%. Top gainers within the industry include WellCare Health Plans ( WCG), up 5.4%, CareFusion ( CFN), up 1.7%, Hologic ( HOLX), up 1.6% and Varian Medical Systems ( VAR), up 0.9%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.90 (-2.2%) to $40.94 on heavy volume. Thus far, 574,917 shares of Grifols exchanged hands as compared to its average daily volume of 606,600 shares. The stock has ranged in price between $40.55-$41.57 after having opened the day at $41.49 as compared to the previous trading day's close of $41.84. Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $14.3 billion and is part of the health care sector. The company has a P/E ratio of 41.2, above the S&P 500 P/E ratio of 17.7. Shares are up 15.8% year-to-date as of the close of trading on Monday. Currently there are 4 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold. TheStreet Ratings rates Grifols as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Grifols Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
